Cambridge Isotope Laboratories, Inc. (CIL) is the world leader in the separation and manufacture of stable isotopes and stable isotope-labeled compounds. With approximately 700 employees and laboratories in five countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (non-radioactive) isotopes of carbon, hydrogen, nitrogen and oxygen.
Our chemists substitute a common atom for a rare, highly valued isotopic component so that the final product can be readily measured or traced using mass spectrometry (mass spec) or nuclear magnetic resonance (NMR). CIL¹s products are utilized in laboratories, medical, government and academic research centers and health care facilities worldwide.
We are proud that CIL products have contributed to medical advancements in cancer research, new drug development, environmental analysis, genomics and proteomics and medical diagnostic research.
CIL¹s vision began when it was founded in 1981 by Dr. Joel Bradley, an organic chemist from MIT. We now produce more than 15,000 products and have ISO 13485 quality systems, as well as cGMP production capabilities. The CIL group is comprised of six companies: Cambridge Isotope Laboratories, Inc. (CIL), CIL Isotope Separations (CIS), CIL Canada, Inc. in Montreal, Canada; Euriso-Top in Saclay, France; ABX GmbH in Dresden, Germany and CIL China.